Hemab Therapeutics Holdings, Inc. (COAG) Current Ratio
- Current ratio · latest quarter: Value 35.85×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 35.85× | Current assets / current liabilities. $464.00M ÷ $12.94M ≈ 35.85× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 464.00M USD | Assets, Current |
| Current obligations | 12.94M USD | Liabilities, Current |
| Cash and equivalents | 237.37M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 220.09M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 6.23M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $464.00M | $12.94M | $237.37M | $220.09M | (m) | (m) | $6.23M | (m) | 35.85× |
| 2026-03-31 | $169.43M | $13.19M | $49.86M | $113.67M | (m) | (m) | $5.68M | (m) | 12.85× |
| 2025-12-31 | $192.55M | $10.68M | $87.97M | $97.51M | (m) | (m) | $5.73M | (m) | 18.03× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |